Sydney, Australia 29 June 2022
Highlights
- Professor Louise Emmett joins Clarity’s Scientific Advisory Board (SAB)
- She is deeply embedded in Australia’s multidisciplinary clinical development and cancer research efforts
- Professor Emmett will continue to be highly active and influential in progressing Clarity’s SAR Technology as both a collaborator and now as a SAB member
- Follows the recent appointment of prostate cancer expert, Dr Neal Shore, in May 2022, and Nuclear Medicine and Theranostics specialist, Dr Andrei Iagaru, in April 2022
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the appointment of leading Nuclear Medicine and Theranostics expert, Professor Louise Emmett, to Clarity’s SAB.
Prof Emmett has been deeply involved and influential in progressing Clarity’s SAR-Bombesin and SAR-bisPSMA products. Earlier this month, she presented data from the pilot diagnostic trial of SAR-Bombesin in breast cancer at the prestigious American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. She has also successfully imaged a number of prostate cancer patients who are PSMA-negative under a Special Access Scheme in Australia, laying groundwork for Clarity’s recently approved US-based Phase II trial with SAR-Bombesin in this indication. Prof Emmett is also Lead Principal Investigator in the Phase I diagnostic SAR-bisPSMA trial in patients with untreated, confirmed prostate cancer in Australia.
Prof Emmett is the Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital Sydney, a conjoint professor of medicine at the University of New South Wales and clinical research leader at the Garvan Institute of Medical Research. Since joining the Nuclear Medicine and Positron Emission Tomography (PET) department at St Vincent’s Hospital in 2012, Prof Emmett has been instrumental in developing the theranostics initiative at the St Vincent’s Campus, introducing new radiopharmaceuticals for clinical and research evaluation of cancer as well as setting up radiopharmacy production of a number of imaging and therapy tracers.
Prof Emmett is heavily involved in multidisciplinary clinical development and cancer research, including both imaging and therapy. She is the principal investigator of a number of prospective randomised national trials in Australia, being a big believer in the power of clinical research to optimise treatments and improve patients’ lives. She is passionate about translational science, collaborating with biotechnology companies to bring promising theranostic agents into the clinic.
Prof Louise Emmett commented on her appointment, “Clarity is at the forefront of developing next-generation Targeted Copper Theranostics (TCTs) and bringing the benefits of centralised manufacture and logistical advantages to the cancer patients and treatment staff alike. Combined with the clinical benefits of Clarity’s products, I believe the TCT platform may play an important role in cementing radiopharmaceuticals’ strong presence in oncology, including large cancer indications, like prostate and breast cancer, by addressing numerous challenges with the current generation of radiopharmaceuticals. I am looking forward to continuing our collaboration with Clarity, now as a member of the SAB, in pursuit of our mutual goal of developing novel radiopharmaceuticals to improve treatment outcomes for children and adults with cancer.”
Clarity’s Executive Chairman, Dr Alan Taylor, commented, “Prof Emmett is a leading expert in radiopharmaceuticals and has been Clarity’s long-term collaborator as we share the passion for translating great Australian science into the clinic. Her incredible expertise in successfully navigating the early-stage clinical trial scene in Australia as well as her in-depth knowledge of the radiopharmaceutical space have been invaluable in swiftly progressing Phase I trials of our SAR-Bombesin and SAR-bisPSMA products in breast and prostate cancers. We are very pleased to welcome Prof Emmett to our SAB. Her appointment follows the recent addition of prostate cancer expert, Dr Neal Shore, as well as Nuclear Medicine and Theranostics specialist, Dr Andrei Iagaru, marking the third key collaborator to increase their support for our Company and technology this year by joining our SAB.”
Prof Emmett completed medical school at Auckland University (1992), New Zealand prior to completing her specialty training in Nuclear Medicine in Sydney and receiving her Fellow of the Royal Australasian College of Physicians (FRACP) qualification in 1999. She undertook a specialty fellowship in Nuclear Cardiology at the University Health Network in Toronto, Canada in 2001, and completed a Doctorate of Medicine in Nuclear Cardiology through Auckland University in 2014. Prof Emmett is a clinical professor with the University of New South Wales with a strong interest in research. She has published over 100 original papers in peer reviewed journals in the last 10 years, has received a number of grants for clinical research and has presented at numerous national and international meetings.
About Clarity
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
Media Contact
Clarity Pharmaceuticals
Dr Alan Taylor
Executive Chairman
+61 (0)413 871 165
ataylor@claritypharm.com
Citadel-MAGNUS
Catherine Strong
0406 759 268
cstrong@citadelmagnus.com
This announcement has been authorised for release by the Executive Chairman.
